
|Videos|June 16, 2011
Dr. Wolchok Describes Candidates for Ipilimumab
Author(s)Jedd D. Wolchok, MD, PhD
Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes Candidates for Ipilimumab
Advertisement
Jedd D. Wolchok, MD, PhD From Memorial Sloan-Kettering Cancer Center describes candidates for ipilimumab.
Dr. Wolchok says many melanoma patients are candidates for ipilimumab, if they have unresectable stage III or stage IV disease. Patients with melanoma that has spread to a distant organ or that has spread to local lymph nodes but can't be surgically removed are patients who, by the current US label, are eligible. The patients who doctors should be careful in using this drug with have a history of autoimmune disease.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
2
FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
3
Subgroup Analyses Confirm Clinically Meaningful Revumenib Responses in AML Across Mutational Profiles
4
Data Support Luspatercept at Maximum-Approved Dose for Transfusion-Dependent Lower-Risk MDS
5







































































